Scanning the Stable Isotopic Structure of Molecules by Tandem Mass Spectrometry
Cajetan Neubauer (1), Michael J. Sweredoski (1), Annie Moradian (1), Dianne K. Newman (1), Richard J. Robins (2), John M. Eiler (1) (1) California Institute of Technology, Pasadena, CA; (2) CNRS-University of Nantes, France
Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
Cajetan Neubauer (Presenter) California Institute of Technology
Presenter Bio: Dr. Caj Neubauer is a biochemist developing methods for stable isotope analysis by mass spectrometry. He is currently a senior postdoc at the Caltech geobiology program and a fellow of the Hanse-Wissenschaftskolleg in Germany (2019-2020). Caj received his BSc and MSc in biochemistry from the Technical University of Munich. For his PhD he studied structures of the translational apparatus at the MRC Laboratory of Molecular Biology. The focus of his research is measuring the activity of microbes in sites of chronic infections, work that has recently lead to determining intramolecular distributions of stable isotopes in metabolites.
Relevant Financial Disclosures
(within past 24 months)
No relevant financial relationship(s) to disclose.
Abstract
The intramolecular distribution of stable isotopes can inform us about the origin and history of a metabolite. This record has largely remained inaccessible for clinical applications because the most diagnostic variants, such as multiply-substituted isotopologues, are challenging to quantify. We have developed a fast mass spectrometric method (M+1 isotope barcoding) that is designed to measure natural-level isotope variations in diverse molecules. This presentation will introduce fundamental concepts of molecular isotopic structure and isotope barcoding. The development of biomarkers that are based on the intramolecular distribution of isotopes, and current technical challenges towards their eventual use in medical diagnostics, will be discussed.
= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
